{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:44:58Z","timestamp":1792683898744,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of Chin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chimeric antigen receptor (CAR) T cells show suboptimal efficacy in acute myeloid leukemia (AML). We find that CAR T cells exposed to myeloid leukemia show impaired activation and cytolytic function, accompanied by impaired antigen receptor downstream calcium, ZAP70, ERK, and C-JUN signaling, compared to those exposed to B-cell leukemia. These defects are caused in part by the high expression of CD155 by AML. Overexpressing C-JUN, but not other antigen receptor downstream components, maximally restores anti-tumor function. C-JUN overexpression increases costimulatory molecules and cytokines through reinvigoration of ERK or transcriptional activation, independent of anti-exhaustion. We conduct an open-label, non-randomized, single-arm, phase I trial of C-JUN-overexpressing CAR-T in AML (NCT04835519) with safety and efficacy as primary and secondary endpoints, respectively. Of the four patients treated, one has grade 4 (dose-limiting toxicity) and three have grade 1\u20132 cytokine release syndrome. Two patients have no detectable bone marrow blasts and one patient has blast reduction after treatment. Thus, overexpressing C-JUN endows CAR-T efficacy in AML.<\/jats:p>","DOI":"10.1038\/s41467-024-50485-9","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T09:02:46Z","timestamp":1721638966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Shiyu","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuojun","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-2616","authenticated-orcid":false,"given":"Qing","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5989-7591","authenticated-orcid":false,"given":"Dongming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8587-3446","authenticated-orcid":false,"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongchao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8785-0336","authenticated-orcid":false,"given":"Jing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2855-5871","authenticated-orcid":false,"given":"Xiaoming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"50485_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"50485_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","volume":"18","author":"P Bose","year":"2017","unstructured":"Bose, P., Vachhani, P. & Cortes, J. E. Treatment of relapsed\/refractory acute myeloid leukemia. Curr. Treat. Options Oncol. 18, 17 (2017).","journal-title":"Curr. Treat. Options Oncol."},{"key":"50485_CR3","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter, R. B. et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J. Clin. Oncol. 29, 1190\u20131197 (2011).","journal-title":"J. Clin. Oncol."},{"key":"50485_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med."},{"key":"50485_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.967754","volume":"12","author":"W Wei","year":"2022","unstructured":"Wei, W. et al. Chimeric antigen receptor T-cell therapy for T-ALL and AML. Front. Oncol. 12, 967754 (2022).","journal-title":"Front. Oncol."},{"key":"50485_CR6","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2020006921","volume":"137","author":"S Willier","year":"2021","unstructured":"Willier, S. et al. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood 137, 1037\u20131049 (2021).","journal-title":"Blood"},{"key":"50485_CR7","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro, F. P. et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia 35, 3282\u20133286 (2021).","journal-title":"Leukemia"},{"key":"50485_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"QS Wang","year":"2015","unstructured":"Wang, Q. S. et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther. 23, 184\u2013191 (2015).","journal-title":"Mol. Ther."},{"key":"50485_CR9","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/fonc.2019.01358","volume":"9","author":"S Yao","year":"2019","unstructured":"Yao, S. et al. Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML. Front. Oncol. 9, 1358 (2019).","journal-title":"Front. Oncol."},{"key":"50485_CR10","first-page":"1359","volume":"130","author":"KD Cummins","year":"2017","unstructured":"Cummins, K. D. et al. Treating relapsed\/refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells. Blood 130, 1359 (2017).","journal-title":"Blood"},{"key":"50485_CR11","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","volume":"27","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute myeloid leukemia. Clin. Cancer Res. 27, 3549\u20133555 (2021).","journal-title":"Clin. Cancer Res."},{"key":"50485_CR12","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.1002\/cam4.5916","volume":"12","author":"K Pei","year":"2023","unstructured":"Pei, K. et al. Anti-CLL1-based CAR T-cells with 4-1-BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia. Cancer Med. 12, 9655\u20139661 (2023).","journal-title":"Cancer Med."},{"key":"50485_CR13","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1091\/mbc.e02-03-0149","volume":"13","author":"H Liu","year":"2002","unstructured":"Liu, H. & Grundstr\u00f6m, T. Calcium regulation of GM-CSF by calmodulin-dependent kinase II phosphorylation of Ets1. Mol. Biol. Cell 13, 4497\u20134507 (2002).","journal-title":"Mol. Biol. Cell"},{"key":"50485_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/jir.1998.18.197","volume":"18","author":"V Aas","year":"1998","unstructured":"Aas, V., Larsen, K. & Iversen, J. G. IFN-gamma induces calcium transients and increases the capacitative calcium entry in human neutrophils. J. Interferon Cytokine Res. 18, 197\u2013205 (1998).","journal-title":"J. Interferon Cytokine Res."},{"key":"50485_CR15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12031-019-1260-1","volume":"67","author":"J Singh","year":"2019","unstructured":"Singh, J., Sharma, K., Frost, E. E. & Pillai, P. P. Role of PDGF-A-activated ERK signaling mediated FAK-paxillin interaction in oligodendrocyte progenitor cell migration. J. Mol. Neurosci. 67, 564\u2013573 (2019).","journal-title":"J. Mol. Neurosci."},{"key":"50485_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12882-022-03001-4","volume":"23","author":"X Dong","year":"2022","unstructured":"Dong, X. & Tang, Y. Ntrk1 promotes mesangial cell proliferation and inflammation in rat glomerulonephritis model by activating the STAT3 and p38\/ERK MAPK signaling pathways. BMC Nephrol. 23, 413 (2022).","journal-title":"BMC Nephrol."},{"key":"50485_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.18","volume":"4","author":"X Sun","year":"2014","unstructured":"Sun, X. et al. Novel function of the chromosome 7 open reading frame 41 gene to promote leukemic megakaryocyte differentiation by modulating TPA-induced signaling. Blood Cancer J. 4, e198 (2014).","journal-title":"Blood Cancer J."},{"key":"50485_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/glia.20653","volume":"56","author":"YS Choi","year":"2008","unstructured":"Choi, Y. S., Cho, H. Y., Hoyt, K. R., Naegele, J. R. & Obrietan, K. IGF-1 receptor-mediated ERK\/MAPK signaling couples status epilepticus to progenitor cell proliferation in the subgranular layer of the dentate gyrus. Glia 56, 791\u2013800 (2008).","journal-title":"Glia"},{"key":"50485_CR19","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0960-9822(00)00512-1","volume":"10","author":"T Kataoka","year":"2000","unstructured":"Kataoka, T. et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr. Biol. 10, 640\u2013648 (2000).","journal-title":"Curr. Biol."},{"key":"50485_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10555-008-9123-1","volume":"27","author":"SM Keyse","year":"2008","unstructured":"Keyse, S. M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 27, 253\u2013261 (2008).","journal-title":"Cancer Metastasis Rev."},{"key":"50485_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-018-0020-8","volume":"18","author":"G Gaud","year":"2018","unstructured":"Gaud, G., Lesourne, R. & Love, P. E. Regulatory mechanisms in T cell receptor signalling. Nat. Rev. Immunol. 18, 485\u2013497 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"50485_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal Transduct. Target. Ther. 6, 412 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"50485_CR23","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.0900092","volume":"182","author":"CA Corzo","year":"2009","unstructured":"Corzo, C. A. et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 182, 5693\u20135701 (2009).","journal-title":"J. Immunol."},{"key":"50485_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4049\/jimmunol.168.2.689","volume":"168","author":"A Mazzoni","year":"2002","unstructured":"Mazzoni, A. et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168, 689\u2013695 (2002).","journal-title":"J. Immunol."},{"key":"50485_CR25","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.7150\/ijbs.41105","volume":"16","author":"S Yang","year":"2020","unstructured":"Yang, S., Wei, W. & Zhao, Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J. Biol. Sci. 16, 1767\u20131773 (2020).","journal-title":"Int J. Biol. Sci."},{"key":"50485_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20, 173\u2013185 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"50485_CR27","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1038\/s41388-018-0288-y","volume":"37","author":"H Stamm","year":"2018","unstructured":"Stamm, H. et al. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene 37, 5269\u20135280 (2018).","journal-title":"Oncogene"},{"key":"50485_CR28","doi-asserted-by":"crossref","unstructured":"Gorvel, L. & Olive, D. Targeting the \"PVR-TIGIT axis\" with immune checkpoint therapies. F1000Res 9, Faculty Rev-354 (2020).","DOI":"10.12688\/f1000research.22877.1"},{"key":"50485_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41590-018-0131-1","volume":"19","author":"WL Lo","year":"2018","unstructured":"Lo, W. L. et al. Lck promotes Zap70-dependent LAT phosphorylation by bridging Zap70 to LAT. Nat. Immunol. 19, 733\u2013741 (2018).","journal-title":"Nat. Immunol."},{"key":"50485_CR30","doi-asserted-by":"publisher","first-page":"102397","DOI":"10.1016\/j.coi.2023.102397","volume":"85","author":"D Schnoegl","year":"2023","unstructured":"Schnoegl, D., Hiesinger, A., Huntington, N. D. & Gotthardt, D. AP-1 transcription factors in cytotoxic lymphocyte development and antitumor immunity. Curr. Opin. Immunol. 85, 102397 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"50485_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880108","volume":"13","author":"H Mu-Mosley","year":"2022","unstructured":"Mu-Mosley, H. et al. Transgenic expression of IL15 retains CD123-redirected T cells in a less differentiated state resulting in improved anti-aml activity in autologous AML PDX models. Front. Immunol. 13, 880108 (2022).","journal-title":"Front. Immunol."},{"key":"50485_CR32","doi-asserted-by":"publisher","first-page":"e001229","DOI":"10.1136\/jitc-2020-001229","volume":"8","author":"P Ataca Atilla","year":"2020","unstructured":"Ataca Atilla, P. et al. Modulating TNF\u03b1 activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J. Immunother. Cancer 8, e001229 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"50485_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute, G. et al. Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants. Cancer Immunol. Res 5, 571\u2013581 (2017).","journal-title":"Cancer Immunol. Res"},{"key":"50485_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep06138","volume":"4","author":"X Mou","year":"2014","unstructured":"Mou, X. et al. The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients. Sci. Rep. 4, 6138 (2014).","journal-title":"Sci. Rep."},{"key":"50485_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bone.2017.05.012","volume":"101","author":"H Mizumachi","year":"2017","unstructured":"Mizumachi, H. et al. Calcium-sensing receptor-ERK signaling promotes odontoblastic differentiation of human dental pulp cells. Bone 101, 191\u2013201 (2017).","journal-title":"Bone"},{"key":"50485_CR36","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1093\/biolre\/ioz222","volume":"102","author":"T N\u2019Tumba-Byn","year":"2019","unstructured":"N\u2019Tumba-Byn, T., Yamada, M. & Seandel, M. Loss of tyrosine kinase receptor Ephb2 impairs proliferation and stem cell activity of spermatogonia in culture\u2020. Biol. Reprod. 102, 950\u2013962 (2019).","journal-title":"Biol. Reprod."},{"key":"50485_CR37","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1158\/0008-5472.CAN-12-0995","volume":"72","author":"S Rizzolio","year":"2012","unstructured":"Rizzolio, S. et al. Neuropilin-1-dependent regulation of EGF-receptor signaling. Cancer Res. 72, 5801\u20135811 (2012).","journal-title":"Cancer Res."},{"key":"50485_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03984-0","volume":"21","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Valtrate, an iridoid compound in Valeriana, elicits anti-glioblastoma activity through inhibition of the PDGFRA\/MEK\/ERK signaling pathway. J. Transl. Med. 21, 147 (2023).","journal-title":"J. Transl. Med."},{"key":"50485_CR39","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/354494a0","volume":"354","author":"T Smeal","year":"1991","unstructured":"Smeal, T., Binetruy, B., Mercola, D. A., Birrer, M. & Karin, M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 354, 494\u2013496 (1991).","journal-title":"Nature"},{"key":"50485_CR40","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1093\/emboj\/cdg388","volume":"22","author":"S Morton","year":"2003","unstructured":"Morton, S., Davis, R. J., McLaren, A. & Cohen, P. A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J. 22, 3876\u20133886 (2003).","journal-title":"EMBO J."},{"key":"50485_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08871-1","volume":"10","author":"M Noviello","year":"2019","unstructured":"Noviello, M. et al. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat. Commun. 10, 1065 (2019).","journal-title":"Nat. Commun."},{"key":"50485_CR42","doi-asserted-by":"publisher","first-page":"e120974","DOI":"10.1172\/jci.insight.120974","volume":"3","author":"HA Knaus","year":"2018","unstructured":"Knaus, H. A. et al. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight 3, e120974 (2018).","journal-title":"JCI Insight"},{"key":"50485_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/imr.12823","volume":"292","author":"C Fenwick","year":"2019","unstructured":"Fenwick, C. et al. T-cell exhaustion in HIV infection. Immunol. Rev. 292, 149\u2013163 (2019).","journal-title":"Immunol. Rev."},{"key":"50485_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03480-x","volume":"20","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Blocking TIGIT\/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer. J. Transl. Med. 20, 280 (2022).","journal-title":"J. Transl. Med."},{"key":"50485_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/imr.12518","volume":"276","author":"WC Dougall","year":"2017","unstructured":"Dougall, W. C., Kurtulus, S., Smyth, M. J. & Anderson, A. C. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol. Rev. 276, 112\u2013120 (2017).","journal-title":"Immunol. Rev."},{"key":"50485_CR46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley, A. M. et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615, 507\u2013516 (2023).","journal-title":"Nature"},{"key":"50485_CR47","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ccell.2019.12.014","volume":"37","author":"C Sun","year":"2020","unstructured":"Sun, C. et al. THEMIS-SHP1 recruitment by 4-1BB tunes LCK-mediated priming of chimeric antigen receptor-redirected T cells. Cancer Cell 37, 216\u2013225.e216 (2020).","journal-title":"Cancer Cell"},{"key":"50485_CR48","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","volume":"8","author":"SA Batra","year":"2020","unstructured":"Batra, S. A. et al. Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol. Res. 8, 309\u2013320 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"50485_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"50485_CR50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","volume":"40","author":"S Heitzeneder","year":"2022","unstructured":"Heitzeneder, S. et al. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell 40, 53\u201369.e59 (2022).","journal-title":"Cancer Cell"},{"key":"50485_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add7900","volume":"15","author":"ER Vander Mause","year":"2023","unstructured":"Vander Mause, E. R. et al. Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity. Sci. Transl. Med. 15, eadd7900 (2023).","journal-title":"Sci. Transl. Med."},{"key":"50485_CR52","doi-asserted-by":"publisher","first-page":"e2104758118","DOI":"10.1073\/pnas.2104758118","volume":"118","author":"DG Gennert","year":"2021","unstructured":"Gennert, D. G. et al. Dynamic chromatin regulatory landscape of human CAR T cell exhaustion. Proc. Natl Acad. Sci. USA 118, e2104758118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"50485_CR53","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"50485_CR54","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1089\/hum.2017.241","volume":"29","author":"S Li","year":"2018","unstructured":"Li, S. et al. CD33-specific chimeric antigen receptor T cells with different co-stimulators showed potent anti-leukemia efficacy and different phenotype. Hum. Gene Ther. 29, 626\u2013639 (2018).","journal-title":"Hum. Gene Ther."},{"key":"50485_CR55","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.3390\/cells9112470","volume":"9","author":"AG Papavassiliou","year":"2020","unstructured":"Papavassiliou, A. G. & Musti, A. M. The multifaceted output of c-Jun biological activity: focus at the junction of CD8 T cell activation and exhaustion. Cells 9, 2470 (2020).","journal-title":"Cells"},{"key":"50485_CR56","doi-asserted-by":"publisher","first-page":"e003149","DOI":"10.1136\/jitc-2021-003149","volume":"9","author":"H Qin","year":"2021","unstructured":"Qin, H. et al. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J. Immunother. Cancer 9, e003149 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"50485_CR57","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med 24, 739\u2013748 (2018).","journal-title":"Nat. Med"},{"key":"50485_CR58","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","volume":"132","author":"F Liu","year":"2018","unstructured":"Liu, F. et al. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood 132, 901 (2018).","journal-title":"Blood"},{"key":"50485_CR59","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439\u20131453.e1419 (2018).","journal-title":"Cell"},{"key":"50485_CR60","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1002\/cpz1.246","volume":"1","author":"RS Huang","year":"2021","unstructured":"Huang, R. S., Lai, M. C. & Lin, S. Ex vivo expansion and CRISPR-Cas9 genome editing of primary human natural killer cells. Curr. Protoc. 1, e246 (2021).","journal-title":"Curr. Protoc."},{"key":"50485_CR61","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.immuni.2020.09.006","volume":"53","author":"M Weulersse","year":"2020","unstructured":"Weulersse, M. et al. Eomes-dependent loss of the co-activating receptor CD226 restrains CD8(+) T cell anti-tumor functions and limits the efficacy of cancer immunotherapy. Immunity 53, 824\u2013839.e810 (2020).","journal-title":"Immunity"},{"key":"50485_CR62","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1182\/blood-2012-03-416040","volume":"120","author":"J Ye","year":"2012","unstructured":"Ye, J. et al. Human regulatory T cells induce T-lymphocyte senescence. Blood 120, 2021\u20132031 (2012).","journal-title":"Blood"},{"key":"50485_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13720","volume":"7","author":"D Laoui","year":"2016","unstructured":"Laoui, D. et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat. Commun. 7, 13720 (2016).","journal-title":"Nat. Commun."},{"key":"50485_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"50485_CR65","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"50485_CR66","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","volume":"40","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell 40, 1407\u20131422.e1407 (2022).","journal-title":"Cancer Cell"},{"key":"50485_CR67","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/nmeth.2688","volume":"10","author":"JD Buenrostro","year":"2013","unstructured":"Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213\u20131218 (2013).","journal-title":"Nat. Methods"},{"key":"50485_CR68","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"50485_CR69","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka, D. et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl. 15, 825\u2013828 (1995).","journal-title":"Bone Marrow Transpl."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50485-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50485-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50485-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T10:08:09Z","timestamp":1721642889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50485-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50485"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-50485-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"13 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6155"}}